Vir Biotechnology price target raised to $110 from $85 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Vir Biotechnology to $110 from $85 and keeps a Buy rating on the shares. The company appears well positioned for the coming chronic hepatitis B virus infection “boom,” the analyst tells investors in a research note. The firm increased its revenue estimates for Vir’s chronic hepatitis B virus franchise, which is the primary driver of the price target increase.